Investors in Pharma

Pureos Bioventures is a venture capital fund, which invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

The MVC manages a €10 million fund by investing equity in start-up companies operating within the digital economy and innovative economic sectors that contribute significant value to the Maltese economy. Eligible companies may include those involved in video game development, fintech, e-sports, life sciences, pharma, green energy, the filming industry, agritech, AI, communications, electronics, financial services, medical devices, software, bluewater industries, and digital technology. Start-up companies operating in innovative economic sectors will have access to the newly established fund, with each start-up being eligible for up to €500,000 in the form of equity investment. The investment by the fund will be pari-passu with that of private venture capital investors. The Malta Government Venture Capital Limited will be the sole entity responsible for administering this scheme.

CofounderZone stands for ecosystem, where two coexisting worlds can find common ground to cooperate. The blue ocean is represented by innovative enterprises, utilising groundbreaking technologies and non-linear business models, but lacking resources to scale. The red ocean is the opposite world, dominated by corporations, struggling to maintain their position, despite being equipped with abundance of knowledge and assets.

Build Collective is an investment company specializing in advisory services and investments. We collaborate closely with engineers and scientists who are pioneering foundational deep technology innovations.

A unique Danish investment and development company.Capnova CAPNOVA invests in tech startups across various sectors, turning innovative ideas into successful businesses with a portfolio of 80+ globally oriented companies.

Novo Holdings is a holding company specializing in life science investor with a focus on creating long-term value.Novo Holdings is a world-leading life science, improving health, sustainability, and generating attractive returns. As the holding and investment company of the Novo Nordisk Foundation,

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany. Established in 2009, it manages a fund of €600 million, investing in biotechnology and technology sectors. The fund focuses on healthcare drug development, life science tools, electronics, and frontier technology and sustainability. M Ventures aims to support visionary companies that develop innovative solutions for treating diseases, advancing scientific research, and addressing sustainability challenges. They take an active role in their portfolio companies, collaborating closely with entrepreneurs and co-investors.

Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in exciting early stage Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her co-investors to participate.

Deep Science Ventures (DSV) is a pioneering venture studio and fund that specializes in the systematic development and investment of science-driven companies. With a unique approach, DSV optimizes the process of turning cutting-edge scientific discoveries into successful commercial ventures. By bridging the gap between academia and entrepreneurship, DSV nurtures interdisciplinary teams to solve complex challenges and create transformative technologies. Through strategic investment and hands-on support, DSV accelerates the growth of startups at the intersection of science, technology, and business, shaping the future of innovation across diverse industries.

Operational Holding Company scouting, investing and supporting high growth potential early stage companies committed to develop Healthcare Innovation. We have a key strategy focus on MedTech industry and Medical Technologies – medical devices, equipment, digital devices and services – which can provide benefit and value for Patients, Doctors and Healthcare Systems and reward Shareholders with a sound and ethical profit .

Aescuvest’s mission is to facilitate and enable impactful investments into medical breakthrough innovation to disrupt and improve healthcare delivery models, products, and services. Aescuvest enables its investors to build their very individual portfolio of healthcare start-ups - according to their personal investment focus.

HTL Innovations provides a seed funding support and a minority financial support. HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). These biopolymers are used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology.HTL Innovations